The Roche way: Spark found a new owner who wants to buy and build a gene therapy leader
For Roche, buying Spark $ONCE for $4.3 billion was just the beginning of a major foray into gene therapies. Now the pharma giant plans to build a new wing of the company around it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
